Jamal Rana: The LDL Cholesterol Goal Post Has Moved
Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:
”Goal post to treat LDL cholesterol has moved in patients with high risk for heart disease. Was thrilled to be part of The Wall Street Journal coverage of the biggest trials presented at AHA Scientific Sessions. We are now in era where multiple options exist to aggressively treat LDL cholesterol in high risk patients to prevent heart disease.
A PCSK9 inhibitor, evolocumab or Repatha, used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo when used in patients without a prior history of myocardial infarction or stroke, the VESALIUS-CV study shows over a median follow-up of 4.6 years.
A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial. IV CTX310 is an in vivo CRISPR-Cas9 gene-editing drug product targeting ANGPTL3.
CORALreef Lipids trial demonstrated that treatment with enlicitide decanoate, once-daily oral PCSK9-inhibitor, resulted in a statistically significant and clinically meaningful reduction in LDL cholestrol.”
Check here for more information.
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology